Table 3 Clinicopathologic characteristics of seven patients positive for RET rearrangements
Study | Age (years) | Sex | Race | Smoking status* | Histology | EGFRstatus | KRASstatus | Dose/day | Exposure | RECIST response | Tumor shrinkage | Reason for discontinuation | RET partner | % cells with rearrangements detected |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vandetanib | ||||||||||||||
ZODIAC | 68 | F | Asian | Non-smoker | Adenocarcinoma | Mutation negative | Negative | 100 mg | 21 days | Progressive disease | – | Progressive disease | KIF5B | 50% |
ZEPHYR | 69 | F | White | Non-smoker | Adenocarcinoma | Mutation negative; amplification positive | Negative | 300 mg | 180 days | Stable disease | 23% shrinkage of target lesions | Adverse event | KIF5B | 75–100% |
ZEPHYR | 59 | F | Asian | Non-smoker | Adenocarcinoma | Mutation negative; amplification positive | Negative | 300 mg | 57 days | Progressive disease | 33% shrinkage of target lesions (progressive disease in non-target lesions) | Progressive disease | KIF5B | 50–75% |
Comparator | ||||||||||||||
ZODIAC | 59 | F | White | Ex-smoker | Adenocarcinoma | Mutation negative | Unknown | – | Six cycles docetaxel | Partial response (day 85); progressive disease (day 210) | 32% shrinkage of target lesions at day 85 | Completed six cycles | KIF5B | 75–100% |
ZEAL** | 58 | M | White | Ex-smoker | Large cell carcinoma | Mutation negative | Negative | – | Five cycles pemetrexed | Progressive disease (day 245) | None | Completed five cycles | Not known | 75–100% |
ZEPHYR | 57 | M | White | Ex-smoker | Adenocarcinoma | Mutation negative | Negative | – | 26 days placebo | Progressive disease (day 25) | None | Progressive disease | KIF5B | 75–100% |
ZEST** | 70 | M | White | Ex-smoker | Adenocarcinoma | Mutation negative; amplification positive | Negative | – | 315 days erlotinib | Progressive disease (day 166) | None | Progressive disease | Not known | 25–50% |